From Analysis:
Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration
Which proteogenomic network hubs identified by multi-omics PD studies are druggable at the earliest stages of neurodegeneration, what are their protein interaction partners in dopaminergic neurons, and do they show altered accessibility in iPSC-derived PD neuron models carrying SNCA mutations?
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
No AI visual card yet
Theorist position for analysis 8ec36980-febb-4093-a5a1-387ea5768480: Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration
Source basis: Key genes and convergent pathogenic mechanisms in Parkinson disease (Nature Reviews Neuroscience, 2024, DOI 10.1038/s41583-024-00812-2). The stored gap context says: Review identified convergent pathogenic mechanisms but highlighted that druggability assessment of network hubs in early PD remains an open challenge.
Primary hypothesis: early PD proteogenomic hubs that are both causal enough and accessible enough to perturb is not mere
Skeptic critique for analysis 8ec36980-febb-4093-a5a1-387ea5768480: Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Key genes and convergent pathogenic mechanisms in Parkinson disease could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: network hubs are often essential, pleiotropic, or inaccessible to safe pharmacologic modulation.
The debate should reject any claim th
Domain expert assessment for analysis 8ec36980-febb-4093-a5a1-387ea5768480: Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test early PD proteogenomic hubs that are both causal enough and accessible enough to perturb in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a trans
{
"ranked_hypotheses": [
{
"title": "early PD proteogenomic hubs that are both causal enough and accessible enough to perturb as proximal driver in Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration",
"description": "early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable proximal phenotype before late disease pathology. The decisive test is multi-omics network centrality, druggability scoring, interactome validation, and SNCA iPSC-neuron perturbation assays.",
"target_gene": "SNCA",
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | open
No comments yet. Be the first to comment!